Skip to main content

Coagulopathy

2
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Entegrion
EntegrionNC - Durham
1 program
1
ResusixPhase 21 trial
Active Trials
NCT03700723Terminated4Est. Apr 2020
Ono Pharmaceutical
Ono PharmaceuticalJapan - Osaka
1 program
1
Camostat MesylatePhase 1/21 trial
Active Trials
NCT04435015Withdrawn0Est. Dec 2021
Octapharma
OctapharmaAustria - Vienna
1 program
Octaplas™N/A1 trial
Active Trials
NCT02037373Terminated43Est. Feb 2018
Haemonetics
HaemoneticsMA - Boston
1 program
RapidTEG testN/A1 trial
Active Trials
NCT01228058Completed1,450Est. Jan 2012
Velico Medical
Velico MedicalMA - Beverly
1 program
Autologous Spray Dried PlasmaPHASE_11 trial
Active Trials
NCT05629338Completed24Est. Apr 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EntegrionResusix
Ono PharmaceuticalCamostat Mesylate
Velico MedicalAutologous Spray Dried Plasma
OctapharmaOctaplas™
HaemoneticsRapidTEG test

Clinical Trials (5)

Total enrollment: 1,521 patients across 5 trials

NCT03700723EntegrionResusix

Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

Start: Dec 2018Est. completion: Apr 20204 patients
Phase 2Terminated
NCT04435015Ono PharmaceuticalCamostat Mesylate

The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

Start: Nov 2021Est. completion: Dec 20210
Phase 1/2Withdrawn
NCT05629338Velico MedicalAutologous Spray Dried Plasma

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

Start: Dec 2022Est. completion: Apr 202524 patients
Phase 1Completed
NCT02037373OctapharmaOctaplas™

Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

Start: Aug 2015Est. completion: Feb 201843 patients
N/ATerminated
NCT01228058HaemoneticsRapidTEG test

A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients

Start: Nov 2010Est. completion: Jan 20121,450 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.